European Pharmaceutical Review

AUGUST 30, 2022

It has highlighted the value of cutting-edge technologies, such as messenger RNA (mRNA) vaccines, and reinforced the industry’s understanding of the power of collaboration, including with contract partners such as contract development and manufacturing organisations (CDMOs). The rise of the nasal vaccine route.

Vaccines 119

Vaccines Immunity Immunization 119

Express Pharma

AUGUST 31, 2023

The global market for mRNA-based oncology therapies is expected to reach a record-breaking $2 billion by 2029. per cent share by 2029, according to GlobalData. If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates.

Immunity 105

Immunity Immunization Vaccines 105

European Pharmaceutical Review

MAY 7, 2024

percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. Injectable vaccines activate the immune system to help to prevent infectious conditions such as influenza. by 2029 appeared first on European Pharmaceutical Review. The market is anticipated to value $1139.4

Vaccines 94

Vaccines Compounding Immunity Immunization 94

European Pharmaceutical Review

SEPTEMBER 1, 2023

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. percent share by 2029, the research has shown. If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates.

Immunization 110

Immunization Immunity Vaccines 110

Express Pharma

NOVEMBER 3, 2023

Pfizer has recently announced the FDA approval of Penbraya, the first and only pentavalent vaccine for coverage against the most common serogroups causing meningococcal disease in people aged 10 to 25 years. Penbraya has the potential to help simplify complex vaccination schedules by providing broader serogroup coverage with fewer doses.”

Vaccines 40

Vaccines Immunity Immunization 40

Pharmaceutical Technology

JUNE 16, 2025

Find out more According to GlobalData’s Acute Lymphocytic Leukemia: Epidemiology Forecast to 2029 report, the number of diagnosed incident cases in the eight major markets (8MM: China, France, Germany, Italy, Japan, Spain, the UK and the US) is projected to increase from 25,636 in 2025 to 26,482 by 2029 at an annual growth rate of 1.16%.

Labelling 52

Labelling Communication Hospitals Vaccines 52